Neil King (University of Washington)
November 2, 2020 05:12 PM ESTUpdated November 3, 08:45 AM
R&D
Coronavirus
In Focus

Can a dark­horse syn­thet­ic bi­ol­o­gy Covid-19 vac­cine one-up the fron­tun­ners? The Gates Foun­da­tion, Am­gen bet 'yes'

Jason Mast

Editor

When the coro­n­avirus broke out, Neil King sat down at a com­put­er at the Uni­ver­si­ty of Wash­ing­ton and de­signed a soc­cer ball.

King, a pro­fes­sor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times